SEC Form 4 · accession 0001209191-18-025908
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bryan M. Reasons
Director
Period of report
Apr 20, 2018
Accepted (ET)
Apr 23, 2018 · 6:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.73 | Apr 20, 2018 | A | 16,000 | A | — | Apr 19, 2028 | Common Stock | 16,000 | 16,000 | D |
Explanation of responses
- F1This option will vest and become exercisable in 36 equal monthly installments through April 20, 2021, subject to the reporting person's continuous service as of such vesting dates.